Aditxt Acquires Appili Therapeutics

Aditxt Signs Share Exchange Agreement to Acquire AiPharma Global Holdings

December 28, 2021

Healthcare Services

Aditxt (Nasdaq: ADTX) signed a share exchange agreement to acquire AiPharma Global Holdings LLC (AiPharma Global) in a two-step transaction involving an initial closing and a secondary closing, subject to conditions including regulatory, board, shareholder, and Nasdaq approvals. The deal would give Aditxt 9.5% of AiPharma at the initial closing and the remaining 90.5% at the secondary closing, with cash payments and Aditxt share issuance at each step.

BiomX Acquires Adaptive Phage Therapeutics

March 18, 2024

Biotechnology

BiomX Inc. completed a stock-for-stock acquisition of Adaptive Phage Therapeutics (APT), making APT a wholly owned subsidiary and combining phage therapy capabilities and pipelines. Concurrently, BiomX raised $50 million in a private placement led by affiliates of Deerfield Management and the AMR Action Fund to advance two Phase 2 assets (BX004 and BX211) toward pivotal readouts in 2025–2026.

Aditxt, Inc. (via Adifem, Inc.) to Merge with Evofem Biosciences, Inc.

November 6, 2024

Healthcare Services

Evofem Biosciences announced it has secured voting agreements from certain Series E-1 stockholders and convertible noteholders to approve its proposed merger with Aditxt’s subsidiary, Adifem, Inc., under an amended and restated merger agreement. The deal would result in Evofem merging into and becoming a wholly owned subsidiary of Aditxt (with the surviving entity described as Evofem). Closing is subject to conditions including stockholder approval and Aditxt raising sufficient capital for approximately $17 million in cash payments (including funding a senior secured noteholder).

Aditxt Enters Revenue-Sharing Agreement with Cellvera in Connection with Proposed Acquisition of Cellvera

April 5, 2022

Biotechnology

Aditxt, Inc. has entered into a revenue-sharing agreement with Cellvera Global Holdings LLC and certain affiliates to support Aditxt’s proposed acquisition of Cellvera. The agreement provides Aditxt with up to 10% of net sales (up to $30 million) while enhancing the security for Cellvera’s loan to Aditxt and extending the due diligence period for the overall transaction.

Aditxt Acquires Ignite Proteomics for $36 Million

March 19, 2026

Healthcare Services

Aditxt announced the $36 million acquisition of Ignite Proteomics, a commercial-stage precision oncology company. The deal was structured through the issuance of 36,000 shares of Aditxt’s newly designated Series A-2 convertible preferred stock, and Ignite will operate as a subsidiary within Aditxt’s oncology initiatives.

Pfizer Acquires Amplyx Pharmaceuticals

April 28, 2021

Biotechnology

Pfizer Inc. acquired Amplyx Pharmaceuticals, a privately held clinical-stage biotechnology company developing the antifungal candidate fosmanogepix (APX001). The deal expands Pfizer's anti-infectives pipeline and secures Amplyx's lead and early-stage assets to advance development of novel antifungal and antiviral therapies.